Printer Friendly

GOVERNMENT CONTRACT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO FORMULATE CANCER AND AIDS DRUGS

GOVERNMENT CONTRACT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY
 TO FORMULATE CANCER AND AIDS DRUGS
 SOMERVILLE, N.J., Jan. 29 /PRNewswire/ -- Unimed, Inc. (NASDAQ: UMED) announced today that a three-year contract in excess of $600,000 has been awarded by the National Cancer Institute (NCI) for the application of Medisperse technology to the development of novel delivery systems for antitumor and anti-AIDS agents.
 Under the contract, the Medisperse technology will be used to develop formulations of poorly soluble compounds for intravenous administration. Compounds which are known, or suspected, to have activity against cancer or AIDS will be supplied by NCI.
 Many of the potential anticancer and anti-AIDS agents currently available for study present solubility and/or stability problems that are beyond the scope of established pharmaceutical formulation approaches. "The Medisperse technology provides a unique approach to solving these formulation problems and, in many applications, can improve bioavailability, facilitate drug targeting and reduce local and systemic toxicity," said Michael R. Violante, Ph.D., inventor of the technology and a managing director of Medisperse, L.P.
 "Involvement in this government program lends further credibility to the Medisperse technology and could potentially identify products for acquisition by Unimed," said Harold J. Tenoso, Ph.D., Unimed's chairman and chief executive officer.
 Medisperse L.P., a joint venture between Unimed, Inc. and Sterilization Technical Services, Inc., (Rochester, N.Y.), a privately owned contract services and technology development company, is commercializing a novel drug formulation and delivery technology with potential application to both therapeutics and diagnostic imaging agents.
 Unimed, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients.
 -0- 1/29/92
 /CONTACT: Charles P. Harrison, president of Unimed, 908-526-6894/
 (UMED) CO: Unimed, Inc. ST: New Jersey IN: MTC SU: CON


TS-OS -- NY007 -- 4570 01/29/92 09:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 29, 1992
Words:306
Previous Article:MAPCO REPORTS EPS OF $4.20 FOR YEAR AND $1.04 FOR FOURTH QUARTER
Next Article:GULFSTREAM AEROSPACE FILES 5 MILLION SHARE INITIAL PUBLIC OFFERING
Topics:


Related Articles
SBIR GRANT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO AIDS THERAPY
SBIR GRANT AWARDED FOR APPLICATION OF MEDISPERSE TECHNOLOGY TO AIDS THERAPY
UNIMED REPORTS REVENUE GROWTH OF 46 PERCENT IN FISCAL FIRST QUARTER
LIDAK PHARMACEUTICALS RECEIVES FEDERAL GRANT FOR STUDIES OF POTENTIAL CANCER THERAPY
RECEPTAGEN LTD. ACQUIRES RYAN PHARMACEUTICALS; GAINS U.S. RIGHTS TO POTENTIAL IMMUNE STIMULANT
RECEPTAGEN LTD. GAINS U.S. RIGHTS TO POTENTIAL IMMUNE STIMULANT; COMPLETES ACQUISITION OF RYAN PHARMACEUTICALS
UNIMED PHARMACEUTICALS ANNOUNCES APPOINTMENT OF PRESIDENT/CEO
ABS Group Inc. Subsidiary Introduces New Products at ACAM Convention, April 24 in Tampa
Isis Wins Industry Week Magazine's Technology and Innovation Award.
GenVec signs contract for preventative AIDS vaccine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters